Equities

Infant Bacterial Therapeutics AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Infant Bacterial Therapeutics AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.18
  • Today's Change0.00 / 0.00%
  • Shares traded500.00
  • 1 Year change--
  • Beta-0.3026
Data delayed at least 15 minutes, as of Feb 19 2026 19:24 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2025202520242023
ASSETS
Cash And Short Term Investments144223329
Total Receivables, Net2.794.776.74
Total Inventory------
Prepaid expenses6.812.465.76
Other current assets, total0.000.00--
Total current assets154231342
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net8.078.899.70
Long term investments0.070.070.07
Note receivable - long term------
Other long term assets----0.00
Total assets162240351
LIABILITIES
Accounts payable444730
Accrued expenses122215
Notes payable/short-term debt--00
Current portion long-term debt/capital leases------
Other current liabilities, total0.390.420.78
Total current liabilities566946
Total long term debt--00
Total debt--00
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities566946
SHAREHOLDERS EQUITY
Common stock3.673.673.67
Additional paid-in capital769769767
Retained earnings (accumulated deficit)(667)(602)(465)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.00--0.00
Total equity105170305
Total liabilities & shareholders' equity162240351
Total common shares outstanding131313
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.